Oral Heparin: A Review of Its Status
Author Information
Author(s): Ehud Arbit, Michael Goldberg, Isabel Gomez-Orellana, Shingai Majuru
Primary Institution: Emisphere Technologies Inc.
Hypothesis
Can a novel oral dosage form of unfractionated heparin be developed to provide effective anticoagulation?
Conclusion
Oral heparin-SNAC can reduce the incidence of proximal venous thrombosis in patients undergoing hip replacement surgery compared to standard LMWH.
Supporting Evidence
- Oral heparin-SNAC was shown to reduce the incidence of DVT in a phase III trial.
- The study involved a large sample size of 2264 patients.
- Oral heparin-SNAC demonstrated a dose-dependent effect on reducing venous thrombosis.
Takeaway
This study is about a new way to take heparin, a blood thinner, by mouth instead of through a needle, which could make it easier for patients.
Methodology
The study involved a phase III trial comparing oral heparin-SNAC to subcutaneous LMWH in patients undergoing elective hip surgery.
Limitations
The study did not meet its primary endpoint, likely due to a suboptimal dosage form and a poorly tasting liquid formulation.
Participant Demographics
Participants included 2264 patients undergoing elective hip surgery.
Statistical Information
P-Value
0.013
Confidence Interval
95% CI for ldSNAC and hdSNAC compared with LMWH were: 5.7% [0.1% to 11.7% CI] and 3.7% [-1.9% to 9.7% CI]
Statistical Significance
p = 0.013
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website